Table 1.
Patient characteristics for ACNS1021 patients who received study drug (n = 29)
| Stratum A Recurrent HGG (n = 16) | Stratum B Recurrent Ependymoma (n = 13) | All Patients Who Received Study Drug (n = 29) | |
|---|---|---|---|
| Age at study enrollment (years) | |||
| Median | 14.5 | 12.0 | 13.4 |
| Range | 4.7–19.9 | 3.0–16.9 | 3.0–19.9 |
| Sex | |||
| Male | 12 | 6 | 18 |
| Female | 4 | 7 | 11 |
| Race | |||
| White people | 13 | 11 | 24 |
| Black people | 3 | 0 | 3 |
| Other | 0 | 2 | 2 |
| ECOG (Zubrod) performance score1 | 7 (44%)7 (44%)2 (12%) | 10 (77%)2 (15%)1 (8%) | 17 (59%)9 (31%)3 (10%) |
| Patient's registry stage | |||
| Local | 10 | 10 | 20 |
| Regional | 1 | 1 | 2 |
| Distant | 1 | 1 | 2 |
| Unknown | 1 | 1 | 2 |
| Not applicable | 3 | 0 | 3 |
| Tumor grade2 | |||
| WHO Grade 2 | 3 | ||
| WHO Grade 3 | 9 | 5 | |
| WHO Grade 4 | 7 | ||
| Number of patients who had prior RT | 15 | 10 | 25 |
| Number of patients who had prior CT | 14 | 8 | 22 |
| Number of sunitinib cycles received | |||
| Median | 1 | 2 | 2 |
| Range | 1–2 | 1–5 | 1–5 |
0: Fully active able to carry on all predisease performance without restriction.
1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house/office work
2: Ambulatory and capable of all self‐care but unable to carry out any work activities. Up and about more than 50% of waking hours.
HGG: high‐grade gliomas; RT: radiation therapy; CT: chemotherapy.
1ECOG performance score definitions. 2Tissue was not available for central pathology review for five of the patients.